Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on May 29, 2025. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding an update on the Company's novel, broad-spectrum influenza PB2 inhibitor.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory disclosure of a press release rather than financial performance data.
Material Changes
The primary material change disclosed is the issuance of a press release on May 29, 2025, providing an update on the Company's influenza PB2 inhibitor program. No financial comparisons to prior periods are included in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the reference of the press release furnished as Exhibit 99.1. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings. No specific guidance, risks, or contingencies are detailed within the body of this 8-K.
Investor Verification Checklist
- Review the full text of the press release dated May 29, 2025, available as Exhibit 99.1, for specific details on the influenza PB2 inhibitor update.
- Verify the trading status of Common Stock (COCP) on The Nasdaq Capital Market.
- Consult the Company's most recent 10-K or 10-Q filings for current financial metrics, as this 8-K does not contain financial statements.